Because hyperactive mTOR is often found in cancer associated with activating mutation in the PI3K/AKT signaling pathway, significant effort has been made to develop therapeutic strategies that target PI3K/AKT signaling for the treatment of cancer. This evidence concerns the gene AKT1 and cancer.